Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jan Shiang Taur"'
Autor:
Jan-Shiang Taur, Chunsheng Zhao, Mahesh Darna, Yang Chang, Yang Lu, Jinzhe Mao, Wendy Cai, Ke Ren, April C. Braddy
Publikováno v:
The AAPS Journal. 25
Publikováno v:
Drug Metabolism Letters. 6:285-291
To provide a fast assessment in predicting P-gp-mediated DDI risk during early stage of drug development, a transcellular P-gp inhibition assay using two concentrations is presented in the present study. The efflux ratios of loperamide in the presenc
Publikováno v:
Xenobiotica. 38:1536-1550
1. The hypotheses tested were to study cimetidine as a substrate of P-glycoprotein (P-gp) and organic cation transport systems and the modulatory effects of eight flavonoid aglycones and glycosides on these transport systems using Caco-2 and LLC-PK1
Autor:
Ganesh Rajaraman, Xiaoyan Chu, Ailan Guo, Sibylle Neuhoff, Imad Hanna, Caroline A. Lee, Heleen M. Wortelboer, Guangqing Xiao, Malin Forsgard, Tetsuo Yamagata, Masoud Jamei, Sophie P Chung, Laurent Salphati, Isabelle Ragueneau-Majlessi, Johan E. Palm, Joann Coleman, Michael P. O'Connor, Praveen Balimane, Anne Y. Pak, Libin Li, Kathleen M. Hillgren, Lei Zhang, Krisztina Herédi-Szabó, Jan Shiang Taur, Joe Bentz, Mitchell E. Taub, Shibing Deng, Elke S Perloff, Dietmar Weitz, Harma Ellens, Cindy Q. Xia, Christoph Funk, Dallas Bednarczyk
Publikováno v:
Drug Metabolism and Disposition, 7, 41, 1367-1374
In the 2012 Food and Drug Administration (FDA) draft guidance on drug-drug interactions (DDIs), a new molecular entity that inhibits Pglycoprotein (P-gp) may need a clinical DDI study with a P-gp substrate such as digoxin when themaximumconcentration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6f60f0f2a333fa7a0b3ee295536585
https://europepmc.org/articles/PMC3684818/
https://europepmc.org/articles/PMC3684818/
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 41(4)
Eribulin is a new anticancer agent currently in Phase III clinical trials for the treatment of metastatic breast cancer. In the current studies, we have investigated the effects of P-glycoprotein (P-gp) on the in vivo disposition of eribulin using CF